Top Markets
Coin of the day
CTI BioPharma Corp. CTI BioPharma Corp.

CTI BioPharma Corp.

CTIC
Clasificación en acciones #12604
CTI BioPharma Corp. is a biopharmaceutical company dedicated to the discovery,... CTI BioPharma Corp. is a biopharmaceutical company dedicated to the discovery, advancement, and commercialization of innovative, targeted treatments for blood cancers within the United States. Its key product is VONJO (pacritinib), an oral kinase inhibitor currently under investigation, specifically designed to target JAK2, FLT3, IRAK1, and CSF1R for the management of adult patients with myelofibrosis. The company holds licensing and collaboration agreements with Teva Pharmaceutical Industries Ltd., SBIO Pte Ltd., and Baxalta. Established in 1991 and based in Seattle, Washington, CTI BioPharma Corp. was previously known as Cell Therapeutics, Inc., adopting its current name in May 2014.
Precio por acción
$9.09
Última sincronización: 2023-06-23
Capitalización bursátil
$567.77M
Cambio (1 día)
0.00%
Cambio (1 año)
0.00%
País
US
Comercio CTI BioPharma Corp. (CTIC)

Categoría

Ganancias de CTI BioPharma Corp. (CTIC)
Ganancias en 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di CTI BioPharma Corp., gli utili attuali della società sono 0. Nel 2026, la società ha registrato un utile di 0, igual a agli utili del 2026, che erano di 0. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Historial de ganancias de CTI BioPharma Corp. desde 2026 hasta 2026
Ganancias al final de cada año
Año Ganancias Cambiar
Not enough data for the provided dates.
Ganancias de empresas similares o competidoras
Empresa Ganancias Diferencia de ganancias País
$5.27B -
US
$1.95B -
NL
$-4.02B -
AU
$-3.09B -
US
- -
CH